Geron Corporation (GERN)

Currency in USD
1.0800
+0.1500(+16.13%)
Closed·
1.0700-0.0100(-0.93%)
·
Earnings results expected today
GERN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.96111.0800
52 wk Range
0.84002.0100
Key Statistics
Prev. Close
0.93
Open
1.01
Day's Range
0.9611-1.08
52 wk Range
0.84-2.01
Volume
26.8M
Average Vol. (3m)
12.31M
1-Year Change
-6.087%
Book Value / Share
0.34
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GERN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
3.6250
Upside
+235.65%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory

Geron Corporation News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

4 Buy
1 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 3.6250
(+235.65% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Wedbush
Buy5.00+362.96%6.00MaintainOct 28, 2026
TD Cowen
Buy3.00+177.78%4.00MaintainJan 29, 2026
H.C. Wainwright
Hold---MaintainDec 12, 2025
H.C. Wainwright
Hold---MaintainDec 09, 2025
Leerink Partners
Buy2.00+85.19%3.00MaintainNov 05, 2025

Geron Corporation SWOT Analysis


Path to Profitability
Financial trajectory shows meaningful progress with projected EPS improving from negative $0.11 to negative $0.05, supported by favorable biotech sector dynamics
Price Target Outlook
Analysts maintain Overweight rating with $4.00 price target, representing substantial upside from current levels despite near-term execution challenges
Leadership Renewal
New CEO brings strategic reset potential, though tangible results from fresh management direction will require several months to materialize and execute
Commercial Headwinds
Geron's flagship oncology therapeutic Rytelo faces revised sales expectations as market penetration proceeds slower than anticipated amid competitive pressures
Read full SWOT analysis

Geron Corporation Earnings Call Summary for Q3/2026

  • Q3 2026 revenue rose 27% YoY to $60.1M, missing consensus by $0.5M; shares gained 4.29% premarket on sustained demand growth trajectory.
  • Company reaffirmed FY 2026 revenue guidance of $220M-$240M, targeting mid-to-high end; cut operating expense outlook by $10M to $220M-$230M.
  • RYTELO posted fourth consecutive quarter of demand growth, up 10% sequentially; prescriber base expanded 8% to over 1,700 accounts since launch.
  • Cash position strengthened to $339M from $327M prior quarter; gross-to-net deductions improved to 19.3% from 21.6% year-ago, aiding profitability.
  • Germany launch expected by end-2026, France in 2027; management pursuing BD opportunities in hematology/oncology aligned with community care model.
Last Updated: 11/04/2026, 08:45 AM
Read Full Transcript

Earnings

Latest Release
Nov 04, 2026
EPS / Forecast
-- / -0.01
Revenue / Forecast
60.19M / 60.69M
EPS Revisions
Last 90 days

GERN Income Statement

Compare GERN to Peers and Sector

Metrics to compare
GERN
Peers
Sector
Relationship
P/E Ratio
−8.8x−2.6x−0.3x
PEG Ratio
−0.370.000.00
Price / Book
2.7x2.9x2.6x
Price / LTM Sales
2.9x14.3x2.8x
Upside (Analyst Target)
235.6%110.7%67.2%
Fair Value Upside
Unlock−13.1%10.1%Unlock

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company’s product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
159.17M24.77%147.88M
Other Institutional Investors
468.23M72.88%435.04M
Public Companies & Retail Investors
15.07M2.35%14.00M
Total
642.47M100.00%596.92M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.7.64%49,115,57145,633
RA Capital Management, L.P.6.66%42,809,75139,775

People Also Watch

27.970
VKTX
+7.21%
136.50
CRDO
-9.55%
48.42
CRWV
-9.90%
45.82
BSX
+5.32%
626.71
LITE
-7.86%

FAQ

What Is the Geron (GERN) Stock Price Today?

The Geron stock price today is 1.0800 USD.

What Stock Exchange Does Geron Trade On?

Geron is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Geron?

The stock symbol for Geron is "GERN."

What Is the Geron Market Cap?

As of today, Geron market cap is 597.5000M USD.

What Is Geron's Earnings Per Share (TTM)?

The Geron EPS (TTM) is -0.10.

From a Technical Analysis Perspective, Is GERN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Geron Stock Split?

Geron has split 0 times.

How Many Employees Does Geron Have?

Geron has 258 employees.

What is the current trading status of Geron (GERN)?

As of Nov 04, 2026, Geron (GERN) is trading at a price of 1.0800 USD, with a previous close of 0.9300 USD. The stock has fluctuated within a day range of 0.9611 USD to 1.0800 USD, while its 52-week range spans from 0.8400 USD to 2.0100 USD.

What Is Geron (GERN) Price Target According to Analysts?

The average 12-month price target for Geron is 3.6250 USD, with a high estimate of 5 USD and a low estimate of 2.5 USD. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +235.65% Upside potential.

What Is the GERN Premarket Price?

GERN's last pre-market stock price is 1.0200 USD. The pre-market share volume is 446,690.0000, and the stock has decreased by 0.0900, or 9.6800%.

What Is the GERN After Hours Price?

GERN's last after hours stock price is 1.0700 USD, the stock has decreased by -0.0100, or -0.9300%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.